Immutep (IMMP) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immutep (IMMP) has outperformed TransCode Therapeutics (RNAZ) over the past year, gaining 80.8% versus a loss of 86.6%. Over five years, IMMP leads with a -8.5% price change compared with -100.0% for RNAZ. Immutep is the larger company by market cap ($22.9 million vs $20.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | RNAZ |
|---|---|---|
| Share price | $3.11 | $1.16 |
| Market cap | $22.92M | $20.07M |
| 1-day change | -9.06% | -10.77% |
| YTD return | +8.74% | -83.02% |
| 1-year return | +80.81% | -86.57% |
| 5-year return | -8.53% | -100.00% |
| EPS (TTM) | $-7.30 | $-47.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-34.66M |
| 52-week high | $70.60 | $12.60 |
| 52-week low | $2.66 | $1.01 |
| Distance from 52-week high | -95.59% | -90.79% |
| Analyst consensus | none | — |
| Avg. price target upside | +864.63% | — |
| Average volume | 26.07K | 52.03K |
| Shares outstanding | 7.37M | 17.30M |
| Employees | — | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed RNAZ by 167.4 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
IMMP vs RNAZ FAQ
Which is bigger, Immutep or TransCode Therapeutics?
Immutep (IMMP) is larger, with a market capitalization of $22.92M compared with $20.07M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, IMMP or RNAZ?
IMMP returned +80.81% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.